Intensive care unit delirium in patients with severe COVID-19: A prospective observational cohort study.

Q3 Medicine
Ryan J Smith, Christian Lachner, Vijay P Singh, Rodrigo Cartin-Ceba
{"title":"Intensive care unit delirium in patients with severe COVID-19: A prospective observational cohort study.","authors":"Ryan J Smith,&nbsp;Christian Lachner,&nbsp;Vijay P Singh,&nbsp;Rodrigo Cartin-Ceba","doi":"10.4103/ijciis.ijciis_93_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Delirium is common in patients with severe coronavirus disease-19 (COVID-19). The purpose of our study was to determine whether severe COVID-19 is an independent risk factor for the development of delirium in patients treated in the intensive care unit (ICU).</p><p><strong>Methods: </strong>This prospective observational cohort study involved 162 critically ill patients admitted to a multidisciplinary ICU during 2019 and 2020. A validated screening tool was used to diagnose delirium. Multiple delirium risk factors were collected daily including clinical characteristics, hospital course, lab values, vital signs, surgical exposure, drug exposure, and COVID-19 characteristics. After univariate analysis, a multivariate logistic regression analysis was performed to determine independent risk factors associated with the development of delirium.</p><p><strong>Results: </strong>In our study population, 50 (31%) patients developed delirium. A total of 39 (24.1%) tested positive for COVID-19. Initial analysis showed COVID-19 to be more prevalent in those patients that developed delirium (40% vs. 17%; <i>P</i> = 0.003). Multivariate analysis showed opioid use (odds ratio [OR]: 24 [95% confidence intervals (CI): 16-27]; <i>P</i> ≤ 0.001), benzodiazepine use (OR: 23 [95% CI: 16-63] <i>P</i> = 0.001), and estimated mortality based on acute physiology and chronic health evaluation IV score (OR: 1.04 [95% CI: 1.01-1.07] <i>P</i> = 0.002) to be independently associated with delirium development. COVID-19 (OR: 1.44 [95% CI: 0.13-10.6]; <i>P</i> = 0.7) was not found to be associated with delirium.</p><p><strong>Conclusion: </strong>Delirium is prevalent in critically ill patients admitted to the ICU, including those with COVID-19. However, after adjustment for important covariates, we found in this cohort that COVID-19 was not an independent risk factor for delirium.</p>","PeriodicalId":13938,"journal":{"name":"International Journal of Critical Illness and Injury Science","volume":"12 2","pages":"61-69"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285129/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Critical Illness and Injury Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijciis.ijciis_93_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4

Abstract

Background: Delirium is common in patients with severe coronavirus disease-19 (COVID-19). The purpose of our study was to determine whether severe COVID-19 is an independent risk factor for the development of delirium in patients treated in the intensive care unit (ICU).

Methods: This prospective observational cohort study involved 162 critically ill patients admitted to a multidisciplinary ICU during 2019 and 2020. A validated screening tool was used to diagnose delirium. Multiple delirium risk factors were collected daily including clinical characteristics, hospital course, lab values, vital signs, surgical exposure, drug exposure, and COVID-19 characteristics. After univariate analysis, a multivariate logistic regression analysis was performed to determine independent risk factors associated with the development of delirium.

Results: In our study population, 50 (31%) patients developed delirium. A total of 39 (24.1%) tested positive for COVID-19. Initial analysis showed COVID-19 to be more prevalent in those patients that developed delirium (40% vs. 17%; P = 0.003). Multivariate analysis showed opioid use (odds ratio [OR]: 24 [95% confidence intervals (CI): 16-27]; P ≤ 0.001), benzodiazepine use (OR: 23 [95% CI: 16-63] P = 0.001), and estimated mortality based on acute physiology and chronic health evaluation IV score (OR: 1.04 [95% CI: 1.01-1.07] P = 0.002) to be independently associated with delirium development. COVID-19 (OR: 1.44 [95% CI: 0.13-10.6]; P = 0.7) was not found to be associated with delirium.

Conclusion: Delirium is prevalent in critically ill patients admitted to the ICU, including those with COVID-19. However, after adjustment for important covariates, we found in this cohort that COVID-19 was not an independent risk factor for delirium.

重症监护病房重症COVID-19患者谵妄:一项前瞻性观察队列研究
背景:谵妄在重症冠状病毒病-19 (COVID-19)患者中很常见。本研究的目的是确定重症COVID-19是否是重症监护病房(ICU)患者发生谵妄的独立危险因素。方法:本前瞻性观察队列研究纳入了2019年至2020年在多学科ICU住院的162例危重患者。一种有效的筛选工具用于诊断谵妄。每天收集多种谵妄危险因素,包括临床特征、住院病程、实验室值、生命体征、手术暴露、药物暴露和COVID-19特征。单因素分析后,进行多因素logistic回归分析,以确定与谵妄发展相关的独立危险因素。结果:在我们的研究人群中,50例(31%)患者出现谵妄。共有39人(24.1%)感染新冠病毒。初步分析显示,COVID-19在出现谵妄的患者中更为普遍(40%对17%;P = 0.003)。多变量分析显示阿片类药物使用(优势比[OR]: 24[95%可信区间(CI): 16-27];P≤0.001)、苯二氮卓类药物使用(OR: 23 [95% CI: 16-63] P = 0.001)和基于急性生理和慢性健康评估IV评分的估计死亡率(OR: 1.04 [95% CI: 1.01-1.07] P = 0.002)与谵妄发展独立相关。COVID-19 (or: 1.44 [95% ci: 0.13-10.6];P = 0.7)未发现与谵妄相关。结论:谵妄在ICU重症患者中普遍存在,包括新冠肺炎患者。然而,在对重要协变量进行调整后,我们在该队列中发现COVID-19不是谵妄的独立危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
37
期刊介绍: IJCIIS encourages research, education and dissemination of knowledge in the field of Critical Illness and Injury Science across the world thus promoting translational research by striking a synergy between basic science, clinical medicine and public health. The Journal intends to bring together scientists and academicians in the emergency intensive care and promote translational synergy between Laboratory Science, Clinical Medicine and Public Health. The Journal invites Original Articles, Clinical Investigations, Epidemiological Analysis, Data Protocols, Case Reports, Clinical Photographs, review articles and special commentaries. Students, Residents, Academicians, Public Health experts and scientists are all encouraged to be a part of this initiative by contributing, reviewing and promoting scientific works and science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信